Oruka Therapeutics, Inc. (ORKA)
NASDAQ: ORKA · Real-Time Price · USD
13.16
-1.13 (-7.91%)
Feb 6, 2025, 3:34 PM EST - Market open
Oruka Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Oruka Therapeutics stock have an average target of 39.67, with a low estimate of 20 and a high estimate of 49. The average target predicts an increase of 201.44% from the current stock price of 13.16.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Oruka Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 6 | 6 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wolfe Research | Wolfe Research | Buy Initiates $20 | Buy | Initiates | $20 | +51.98% | Feb 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +241.95% | Dec 20, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +241.95% | Nov 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $45 | Strong Buy | Reiterates | $45 | +241.95% | Oct 31, 2024 |
| Stifel | Stifel | Strong Buy Initiates $49 | Strong Buy | Initiates | $49 | +272.34% | Oct 11, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
| Revenue | 2019 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| High | n/a | n/a | n/a | |
| Avg | n/a | n/a | n/a | |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
EPS Forecast
| EPS | 2019 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| High | -55.69 | -1.64 | -1.67 | |
| Avg | -54.10 | -3.48 | -2.98 | |
| Low | -51.98 | -4.76 | -8.44 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.